LOUISVILLE, Colo., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer, and Robin Cowie, Chief Financial Officer, will participate in three upcoming investor conferences: Craig-Hallum 15th Annual Alpha Select Conference1x1 MeetingsDate: Tuesday, November 19, 2024Location: New York, NY Wolfe Research Healthcare Conference 20241x1 MeetingsDate: Wednesday, November 20, 2024Loc ...

Biodesix, Inc. (NASDAQ:BDSX) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Chris Brinzey - IR Scott Hutton - CEO Robin Harper Cowie - CFO Conference Call Participants Andrew Brackmann - William Blair Thomas Flaten - Lake Street Capital Markets Operator Good day and thank you for standing by. Welcome to the Biodesix Q2 2024 Earnings Conference Call. [Operator Instructions]. I would now like to hand the conference over to your speaker today. Chris Brinzey, Investor Relations, ...

Biodesix, Inc. (BDSX) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.17 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 11.11%. A quarter ago, it was expected that this company would post a loss of $0.15 per share when it actually produced a loss of $0.14, delivering a surprise of 6.67%. Over the last four quarters, the company has surpassed ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share BDSX The NASDAQ Global Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commi ...

Exhibit 99.1 Biodesix Announces Second Quarter 2024 Results and Highlights Q2 2024 revenue grew 51% over Q2 2023 to $17.9 million; Q2 2024 gross profit margin of 78.4%, a 5.7% improvement from Q2 2023; Raises full-year 2024 revenue guidance to $70-72 million from $65-68 million; Q2 24 Net loss, including certain non-cash items, and Adjusted EBITDA improved by 19% and 38% over Q2 2023; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, CO, August 7, 2024 – Biodesix, Inc. (Nasdaq: BDSX), a leading ...

Biodesix, Inc. (NASDAQ:BDSX) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants Scott Hutton - CEO Robin Harper Cowie - CFO Chris Brinzey - IR Conference Call Participants Andrew Brackmann - William Blair Kyle Mikson - Canaccord Genuity Thomas Flaten - Lake Street Capital Markets Operator Welcome to the Biodesix Q1 2024 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over to your ...

Biodesix, Inc. (BDSX) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.24 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 6.67%. A quarter ago, it was expected that this company would post a loss of $0.11 per share when it actually produced a loss of $0.10, delivering a surprise of 9.09%.Over the last four quarters, the company has surpassed c ...

Note 2 – Summary of Significant Accounting Policies Basis of Presentation Restricted cash consists of deposits related to the Company's corporate credit card. As of March 31, 2024 and December 31, 2023, the Company had $0.1 million restricted cash, respectively, which was included in 'Other current assets' in the accompanying condensed balance sheets. Inventory Inventory consists primarily of material supplies, which are consumed in the performance of testing services and charged to 'Direct costs and expens ...

i biodesix First quarter 2024 Total Revenue of $14.8 million, a year-over-year increase of 64%, and 7th consecutive quarter of >50% growth in Lung Diagnostic test volume; Raised $55 million in gross proceeds from an oversubscribed and upsized underwritten public offering of common stock and concurrent private placement in April 2024; LOUISVILLE, CO, May 8, 2024 – Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced its financial and operating re ...

Start Time: 08:30 January 1, 0000 9:16 AM ET Biodesix, Inc. (NASDAQ:BDSX) Q4 2023 Earnings Conference Call March 01, 2024, 08:30 AM ET Company Participants Scott Hutton - CEO Robin Harper Cowie - CFO Chris Brinzey - IR Conference Call Participants Andrew Brackmann - William Blair Kyle Mikson - Canaccord Genuity Madison Pasterchick - Morgan Stanley Operator Good day and thank you for standing by. Welcome to the Biodesix's Fourth Quarter 2023 Earnings Conference Call. [Operator Instructions]. Please be advise ...